
    
      This Phase I trial will be the first trial with CD20 CAR transduced T cells in Europe
      targeting melanoma. The rationale for the trial is based on the finding that melanoma cancer
      sustaining cells express CD20 and that targeting CD20+ cells in preclinical model has a
      strong antitumor effect.
    
  